IRBM, an integrated Contract Research Organization (CRO) specializing in preclinical drug discovery, has established a ...

IRBM, has established a comprehensive Functional Genomics Platform to support genetic target identification and validation, ...

Researchers designed a CRISPR-based test that rapidly detects low levels of pathogen genetic material in blood. This is done without the need for nucleic acid amplification.

Leading artificial intelligence (AI) driven drug discovery and bioinformatics, Dr. Sita Sirisha Madugula is making ...

Researchers designed a CRISPR-based test that rapidly detects low levels of pathogen genetic material in blood. This is done without the need for nucleic acid amplification.

Intellia has reported results from a phase 2 trial of its gene-editing drug for hereditary angioedema (HAE) that it says build the case for the drug as a phase 3 trial gets underway – but its ...

Researchers designed a CRISPR-based test that rapidly detects low levels of pathogen genetic material in blood. This is done ...

A first patient has been treated in a trial of an Allergan and Editas drug based on CRISPR/Cas9, a technology that allows genes to be manipulated inside the body. The two companies claim AGN ...

Cancer continues to be a formidable challenge globally, with traditional drug discovery methods focusing on cytotoxic agents and targeted therapies altering the landscape of cancer prognosis and ...

Today, a brief rundown of news involving Novo Nordisk and DBV Technologies, as well as updates from Arbutus Biopharma, Bicycle Therapeutics and CRISPR Therapeutics that you may have missed. Aurion is ...